A Open-Labeled, Non-Controlled Study for Formestane Cream in Healthy Volunteers

Status

Active, not recruiting

Phases

Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR1900022068

Enrollment

Unknown

Registered

2019-03-23

Start date

2019-04-01

Completion date

Unknown

Last updated

2019-03-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

breast cancer

Interventions

1:Formestane cream

Eligibility

Sex/Gender

Female

Age

48 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1 8 postmenopausal healthy women; 2 BMI between 18.5-32; 3 No medical treatment was received within the past month before the trail (including but not limited to essential oils containing hormones, drugs, etc.).

Exclusion criteria

Exclusion criteria: 1. Blood routine: (a) If WBC, RBC, HB, PLT, N% and L% are significantly abnormal. (b) If the WBC is elevated or lowered, slightly elevated or decreased parameters are acceptable. 2. Urine routine: a number of indicators are significantly abnormal. 3. Blood biochemistry (liver and kidney function)are significantly abnormal: (a) total protein reduction. (b) Liver function (ALT, AST) and elevated creatinine (Crea). (b) Those with abnormal c-reactive protein. 4. ECG: Sinus bradycardia (heart rate < 55 times/min), and other abnormal ECG. 5. Chest x-ray: lung lesions. 6. Ultrasound of breast: BI-RADS-0,2,3,4,5 or 6.

Design outcomes

Secondary

Measure	Time frame
Formestane and its metabolites;	—

Countries

China

Contacts

Public ContactWu Bin

1843320672@qq.com+86 15282477373

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026